Ultime notizie per Qantas Airways (OTC:QABSY) Azioni

Qantas Airways

Qantas Airways is Australia's largest domestic airline with typically a two thirds market share, effectively competing in a duopoly with Virgin. The company operates a multibrand strategy, with low-cost carrier Jetstar complementing the full-service Qantas brand. Its frequent-flyer loyalty program continues to expand with new partnerships, which are integral to retaining customer loyalty for its core airline business.

QANTAS AIR LTD S/ADR NEW by Qantas Airways Ltd.

Qantas Airways Ltd

WIIM

TIXT

TELUS shares are trading higher after the company announced it proposed the acquisition of TELUS Digital to accelerate AI and SaaS transformation across core business sectors.

News

CACI

CACI International Awarded 7-Yr Task Order With Estimated Ceiling Of $437M For Support To U.S. Africa Command's Mission

<ul>
<li>LVAD patients face a high risk of bleeding events associated with oral anticoagulation alongside increased risk of cardiovascular (CV) events such as stroke</li>
<li>Hospitalization costs for patients following a major bleeding event associated with oral anticoagulation use averages $39,000 per event</li>
<li>Tecarfarin, with its novel metabolic pathway, potentially may offer an alternative to warfarin in this vulnerable population</li>
</ul>
Cadrenal Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVKD#NASDAQ">CVKD</a>), a biopharmaceutical company developing novel therapeutics for patients with cardiovascular disease, today announced new findings from third-party research on the economic and medical burdens faced by advanced heart failure patients with left ventricular assist devices (LVAD) requiring chronic anticoagulation.
The research recently conducted by Guidehouse, an AI-led professional services firm delivering advisory, technology, and managed services to the commercial and government sectors, underscores the significant clinical and economic burden for LVAD patients who require chronic oral anticoagulation. Key findings include:
<ul>
<li>Major bleeds remain a primary cost driver, with average hospitalization costs (per event) of $54,100 for intracranial hemorrhage, $26,900 for gastrointestinal bleeds, and $36,600 for other major bleeds.</li>
</ul>
Guidehouse's analysis also identified tecarfarin – a novel, Phase 3–ready oral anticoagulant being developed by Cadrenal – as a potential alternative to warfarin to address the current unmet need in this patient population. Tecarfarin is designed to provide more consistent anticoagulation control by avoiding the multiple metabolic pathways associated with warfarin. Its unique metabolism via a single enzyme (CES2) may reduce the risk of drug interactions, dietary complications, and adverse bleeding or thrombotic events.

Biotech

General

CVKD

Cadrenal Therapeutics Highlights Tecarfarin As Safer Anticoagulant Alternative For High-Risk LVAD Patients

PPTA

Perpetua Resources shares are trading lower after the company announced a $300 million bought financing deal and a $100 million private placement.

ZENA

ZenaTech's ZenaDrone To Filed Patent And Accelerate Deployment Of Counter-UAS Technology

Today Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) and DICK'S Sporting Goods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) announced a new partnership that brings the retailer's broad selection of sporting goods, athletic apparel, footwear, team sports gear, golf equipment, fan merchandise and more to the Uber Eats platform. With over 800 DICK'S Sporting Goods and Golf Galaxy locations across the country available on Uber Eats beginning this week, customers can enjoy convenient, on-demand or scheduled delivery of the retailer's hottest products—all at the tap of a button.
Starting today, athletes, fans, and outdoor enthusiasts alike can browse and purchase a wide range of products—from fitness equipment and cleats to golf balls and team jerseys—directly through the Uber Eats app. To celebrate the launch, new and existing Uber Eats users can take advantage of up to 30% off of select athletic essentials, sport accessories and outdoor gear†. As always, Uber One members enjoy added perks, including $0 Delivery Fees on eligible orders††.

UBER

Uber Eats Partners With DICK'S Sporting Goods To Offer On-Demand Delivery Of Sporting Goods Nationwide

– Potential to Address a Broad Range of Complement-Mediated Diseases with Initial Focus on Immune Platelet Transfusion Refractoriness and Refractory Antiphospholipid Syndrome –
– Data Readouts Expected from Cohort 1 in 3Q 2025 and Cohort 2 in 4Q 2025 –
Rallybio Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the initiation of dosing in a Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) study evaluating RLYB116, the Company's innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor.
Additionally, Rallybio announced that the initial indication focus for RLYB116 will be on two hematologic conditions with significant unmet need: immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). Patients suffering from these potentially life-threatening conditions have no approved or effective therapeutic options.

RLYB

Rallybio Initiates Dosing In Phase 1 Confirmatory PK/PD Study Evaluating RLYB116, Subcutaneously Injected C5 Inhibitor

Equinox Gold shares are trading lower. The company updated its FY25 guidance.

Asset Sales

THRD

Third Harmonic Bio Announces Stockholder Approval Of Liquidation And Dissolution Plan With Initial Distribution Expected In The Range Of $5.30-$5.35; Co. Initiates Sale Process Of THB335

BeOne Medicines shares are trading higher after the company announced that the FDA approved a new tablet formulation of BRUKINSA for all five approved indications.

enGene Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.49) by 4.08 percent. This is a 34.21 percent decrease over losses of $(0.38) per share from the same period last year.

Earnings

Earnings Misses

ENGN

enGene Holdings Q2 EPS $(0.51) Misses $(0.49) Estimate

Uxin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UXIN#NASDAQ">UXIN</a>) sees Q2 Total revenues to range between RMB 630M and RMB 660M. &nbsp;

Guidance

UXIN

Uxin Sees Q2 Total revenues to range between RMB 630M and RMB 660M.

Stock Split

Jianzhi Education To Implement ADS Ratio Change From 1 ADS Representing 6 Ordinary Shares To  ADS Representing 60 Shares

Highlights Board's proactive measures to increase long-term stockholder value and record of effective oversight
Urges stockholders to vote "FOR" Oportun's two highly qualified nominees – CEO Raul Vazquez and Carlos Minetti – on the GREEN proxy card
SAN CARLOS, Calif., June 12, 2025 (GLOBE NEWSWIRE) -- Oportun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRT#NASDAQ">OPRT</a>), a mission-driven financial services company, today issued a <a href="https://www.globenewswire.com/Tracker?data=V0jrSm4zoi3E6Szw-O51va69NIDse_FY0wja9KEBqusZ-SLNRJWuToIYodzhYjatz5z05ekZrbP61gohTxAir212gOG8na1IeJH6ykel__fb-JFaebqyvIMF3LP2ZQFp8sGRdd3kH-WMWlDvueIkAZUbhfA1I2VaMit_Q_Wq_8cB-6kTKUQ93OWlZ66u90YWX8EV350qgyrwbnWu2vPLv8wrSv40TET5B31nlm7_oRqk-jN1u14qPVeCowlKErcZ">letter to stockholders</a> from Lead Independent Director Neil Williams detailing the actions that Oportun's Board of Directors has taken to drive improved financial performance and reposition the Company for future success.
After nearly eight years of dedicated service to Oportun's Board, Mr. Williams plans to retire at the Company's upcoming 2025 Annual Meeting of Stockholders. In his letter urging shareholders to vote in favor of Oportun's skilled and experienced nominees, Mr. Williams highlights:
<ul>
<li>In response to the changing economic environment, Oportun announced a detailed plan to reduce expenses and streamline operations in February 2023.</li>
<li>The announcement of that plan took place nearly two months before the Company was aware that Findell Capital Management was a stockholder. Over the next two years, Oportun:
<ul>
<li>Executed multiple reductions in force; eliminated expenses across the organization; initiated a strategic review process for the Company's credit card portfolio that eventually resulted in its sale; and discontinued several non-core businesses.</li>
</ul>
</li>
<li>Oportun has driven $240 million in cost savings since mid-2022, and over the last two quarters returned to GAAP profitability.</li>
<li>Oportun's highly engaged and qualified Board possesses the right mix of skills and experience to continue driving Oportun's strong momentum. The expertise of the Company's nominees, CEO Raul Vazquez and Carlos Minetti, aligns with the needs of the business and provides a strong foundation to guide Oportun moving forward.</li>
</ul>

Management

OPRT

Oportun Urges Shareholders To Support Board Nominees Amid $240M Cost Savings Since Mid-2022 And Returning To Profitability

Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) with a Buy and maintains $12 price target.

Price Target

Analyst Ratings

SNTI

Chardan Capital Maintains Buy on Senti Biosciences, Maintains $12 Price Target

<ul>
<li>Key complex product approval in the Affordable Medicines segment this year</li>
<li>Commercial launch planned for third quarter of 2025</li>
</ul>
BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") today announced the U.S. Food and Drug Administration (FDA) approval of prednisolone acetate ophthalmic suspension, 1% sterile which references Pred Forte&#xAE;. Pred Forte and its design are trademarks of Allergan, Inc., an AbbVie company. Launch of this product is planned for the third quarter of 2025.
Prednisolone acetate ophthalmic suspension, USP 1% is a sterile, topical anti-inflammatory agent for ophthalmic use and is indicated for treating steroid-responsive ocular inflammation.
According to IQVIA&#xAE; U.S. annual sales for prednisolone acetate ophthalmic suspension for the 12 months ended April 2025 were approximately $201 million.

AMRX

Amneal Pharma Announces FDA Approval For Prednisolone Acetate Ophthalmic Suspension; Product Launch Planned For Q3 2025

<a href="https://www.globenewswire.com/Tracker?data=LBI3dZa6X9pqujQP0b3qDtPb4A0mHsbh2E2iwg56HSneVkS2N_njEQ139AbTZxq29Owma6GCvT2xxrpv2eVaT-R-tw3wk31oqBVLm36QEwUEb479QrqH42YKThBSGmn0a4NgDlH5ZtJdTfbIJjGog37ydBMIGikjlEEtdKygzT5oB628atUzd0Fg2EDNJ7nUBQNR0WFS08dl0hLmOZ8HKi9Fyv2mqxBdpGLQEgE7zYblyog2TciMzcuQEAVWfKo0vWDLKUwk-zsgng-X7YgQvA==">BullFrog AI Holdings, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRG#NASDAQ">BFRG</a>, BFRGW))) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced a strategic collaboration with Sygnature Discovery, a leading UK-based contract research organization (CRO) specializing in drug discovery. Through this collaboration, Sygnature will introduce BullFrog Data Networks&#x2122;—BullFrog's proprietary AI-driven data insights platform powered by the bfLEAP&#x2122; engine—to Sygnature's global client base of relevant biopharma companies.
The collaboration marks a significant commercial milestone for BullFrog AI and is expected to greatly accelerate brand recognition and user uptake to generate between $15-$30 million in revenue for BullFrog AI through 2028.

BFRG

BullFrog AI Announces Strategic Collaboration With Sygnature Discovery To Expand AI Platform Reach, Projecting Up To $30M Revenue By 2028

Contracts

JRSH

Jerash Holdings Secures Order From An Omnichannel Retain Corporation; Order Consists Over 3M Pairs Of Shorts

Oceaneering International, Inc. ("Oceaneering") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OII#NYSE">OII</a>) announced today that its Offshore Projects Group ("OPG") segment has entered into a vessel services agreement with a major operator for use of the MPSV Harvey Deep Sea.
The MPSV Harvey Deep Sea, currently chartered by Oceaneering through February 2027, is equipped with two Oceaneering Millennium work class remotely operated vehicles. It is expected to be used by the operator to perform subsea inspection, maintenance, and repair (IMR) and installation services in the Gulf of Mexico.

Oceaneering Secures Vessel Services Agreement For 'Harvey Deep Sea' To Support Subsea Operations

On May 9, 2025, Neo-Concept International Group Holdings Ltd (the "Company") held the Company's Extraordinary General Meeting (the "EGM") , amongst which a share consolidation (the "Share Consolidation") was approved by the shareholders, whereby every five issued and unissued shares (namely, both class A ordinary shares of par value US$0.0000625 each and class B ordinary shares of par value US$0.0000625 each) in the share capital of the Company be consolidated into one (1) share of par value US$0.0003125 each (the "Share Consolidation") so that the authorized share capital of the Company shall be changed from US$50,000 consisting of 800,000,000 shares of par value US$0.0000625 each comprised of 780,000,000 class A ordinary shares of par value US$0.0000625 each and 20,000,000 class B ordinary shares of par value US$0.0000625 each to US$50,000 consisting of 160,000,000 shares of par value US$0.0003125 each comprised of 156,000,000 class A ordinary shares of par value US$0.0003125 each and 4,000,000 class B ordinary shares of par value US$0.0003125 each. The Share Consolidation was to be effective from such date and time to be determined by the board of directors of the Company which in any event shall not be later than 1 July 2025.
The Share Consolidation shall be reflected with the Nasdaq Capital Market and in the marketplace at the open of business on June 16, 2025, whereupon the Class A Ordinary Shares will continue trading under the symbol "NCI" and under the new CUSIP Number of G6421C120.

Neo-Concept International Approves 5-To-1 Share Consolidation At EGM

Fintech

Press Releases

W2 by GO7 joins the UATP Network as its Newest Issuer

Small Cap

Klarna partners with UATP to tap the $1 trillion air travel industry

SAVE THE DATE: REGISTRATION OPENS SOON FOR AIRLINE DISTRIBUTION® 2025

UATP Strengthens 'Buy Now, Pay Later' options with Floa

REGISTRATION NOW OPEN FOR AIRLINE DISTRIBUTION® 2025

EVA Air, Award-Winning Taiwanese Carrier, Becomes Newest UATP Issuer

Copa Airlines Unveils New Support for Key Alternative Payment Methods in Partnership with UATP

Private High-Speed Rail Pioneer iryo Becomes First UATP Rail Merchant in Spain

HRS, Leading Global Corporate Hotel and Meeting Management Platform, Joins UATP Network

Comments

Qantas Airways

Notizie

Ultime notizie per Qantas Airways (OTC:QABSY) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO